Jack Zaremba
Internal Medicine · Birmingham, ALNPI 1104918309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,481 and has fallen 93.4% since, to $98 in 2022.
Across 217 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$609
- AstraZeneca$430
- Amarin Pharma, Inc.$383
- Novo Nordisk$341
- Qiagen, LLC$242
- Pfizer$233
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,374100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $609 |
| AstraZeneca | 33 | $430 |
| Amarin Pharma, Inc. | 25 | $383 |
| Novo Nordisk | 24 | $341 |
| Qiagen, LLC | 2 | $242 |
| Pfizer | 20 | $233 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Astellas Pharma US Inc | 8 | $120 |
| Lilly USA, LLC | 8 | $107 |
| Amgen | 6 | $99 |
| Merck | 6 | $92 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Boehringer Ingelheim | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| GSK | 5 | $67 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Eisai Inc. | 3 | $36 |
| Kowa Pharmaceuticals America, Inc. | 3 | $34 |
| AbbVie | 2 | $24 |
| Abbott | 1 | $19 |
| Boston Scientific | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUTOMATION - QIASTAT$227
How this compares
$3,386 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gemfibrozil | 13 | $28 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Birmingham
- Ryan WeldonBirmingham$458K
- Robert LewisBirmingham$187K
- Thomas HuddleBirmingham$76K
- Jose VargasBirmingham$49K
- Donna FicoBirmingham$46K
- James SullivanBirmingham$39K
- Ross SchumacherBirmingham$26K
- Larry AlfordBirmingham$25K
- David WynneBirmingham$22K
- James CrenshawBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.